Medical information rotating label system for a container

Information

  • Patent Grant
  • 9085402
  • Patent Number
    9,085,402
  • Date Filed
    Thursday, August 16, 2012
    11 years ago
  • Date Issued
    Tuesday, July 21, 2015
    8 years ago
Abstract
The present application is directed to rotating label medical information systems for a container and methods thereof. A base label may be adhered to the container, and medical information displayed on the base label. A top label may cover at least a portion of the base label. The top label may be rotatable about the base label. The top label may have multiple transparent windows allowing multiple items of medical information to be visible through the transparent windows when the top label is rotated about the base label.
Description
FIELD OF THE INVENTION

The present application is directed generally to labels, and more specifically to labels for consumer product containers that illustrate medical information related to medication in the container.


BACKGROUND

Containers for consumer products have a limited amount of outer surface area for placement of labels on the container. This may pose a challenge to manufacturers of these consumer products to fit all of the information they want to deliver to the consumer, or are required by law to deliver to the consumer, in this limited area. In particular, packaging for prescription medications may specify a significant amount of information concerning the condition the medication is intended to treat, as well as the effects of consuming the medication.


Manufacturers of pharmaceuticals and other medical-related packaged products spend millions of dollars each year explaining to consumers how their medication may provide relief for medical conditions. The means of delivery of this information, such as television advertisements, print advertisements, and additional on-package print material, can be very costly and serve to increase the cost of the medication to the consumer. All this effort may ultimately go to waste if the consumer does not take the initiative to seek out and read the information.


Health care professionals often inform patients of medical conditions and the importance of taking prescribed medications using charts and other visual aids. Visual aids may be easier to comprehend and lend themselves to be more readily remembered. However, over time patient may tend to forget the information presented on the visual aid because there is no reinforcement of the information after the patient leaves the office of the health care provider.


SUMMARY

The present application is directed to rotating label medical information systems for a container. An exemplary illustrative rotating label medical information system may comprise a base label adhered to the container. The base label may have a back surface and a front surface, with at least a first and second item of medical information printed on the front surface. The rotating label medical information system may further comprise an opaque rotating top label covering at least a portion of the front surface of the base label. The opaque rotating top label may be rotatable about the base label. In various embodiments, the opaque rotating top label may have a first transparent window and a second transparent window placed within separate portions of the top label allowing at least the first and second items of medical information to be visible through the first transparent window and the second transparent window.


According to additional exemplary embodiments, the present application may be directed to methods for communicating medical information associated with a container. An exemplary method may comprise adhering a base label having a back surface and a front surface to the container, with at least a first and second item of medical information placed on the front surface of the base label. At least a portion of the front surface of the base label may be covered by an opaque rotating top label. A first transparent window and a second transparent window may be placed within separate portions of the opaque rotating top label, such that at least the first and the second items of medical information may be visible through the first transparent window and the second transparent window.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a front view of an exemplary label according to various embodiments.



FIG. 2 is a back view of an exemplary label according to various embodiments.



FIG. 3 is a front view of an exemplary label according to various embodiments.



FIG. 4 is a back view of an exemplary label according to various embodiments.



FIG. 5A illustrates a leading edge of an exemplary label affixed to a container according to various embodiments.



FIG. 5B illustrates an exemplary label secured about a container according to various embodiments.



FIG. 6 illustrates an exemplary label secured about a container according to various embodiments.



FIG. 7 illustrates an exemplary base label secured about a container according to various embodiments.



FIG. 8 illustrates a leading edge of an exemplary top label affixed to an exemplary base label according to various embodiments.



FIG. 9 illustrates an exemplary top label affixed to an exemplary base label and partially wrapped about a container according to various embodiments.



FIG. 10 illustrates an exemplary top label with a window affixed to an exemplary base label and partially wrapped about a container according to various embodiments.



FIG. 11 illustrates an exemplary top label with a window secured about a container and a portion of a base label visible through the window according to various embodiments.



FIG. 12 is a front view of a base label according to various embodiments.



FIG. 13 is a front view of a top label according to various embodiments.



FIG. 14 illustrates an exemplary base label secured about a container according to various embodiments.



FIG. 15A illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 15B illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 15C illustrates an exemplary base label and top label secured about a container according to various embodiments



FIG. 16 is a front view of a base label according to various embodiments.



FIG. 17 is a front view of a top label according to various embodiments.



FIG. 18 illustrates an exemplary base label secured about a container according to various embodiments.



FIG. 19A illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 19B illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 20 is a front view of a base label according to various embodiments.



FIG. 21 is a front view of a top label according to various embodiments.



FIG. 22 illustrates an exemplary base label secured about a container according to various embodiments.



FIG. 23A illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 23B illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 24 is a front view of a base label according to various embodiments.



FIG. 25 is a front view of a top label according to various embodiments.



FIG. 26 illustrates an exemplary base label secured about a container according to various embodiments.



FIG. 27A illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 27B illustrates an exemplary base label and top label secured about a container according to various embodiments.



FIG. 28 is an exemplary flow diagram of a method for communicating medical information associated with a container according to various embodiments.





DETAILED DESCRIPTION

The present application is directed to rotating label medical information systems for a container. An exemplary illustrative rotating label medical information system may comprise a base label adhered to the container. The base label may have a back surface and a front surface, with at least a first and second item of medical information printed on the front surface. The rotating label medical information system may further comprise an opaque rotating top label covering at least a portion of the front surface of the base label. The opaque rotating top label may be rotatable about the base label. In various embodiments, the opaque rotating top label may have a first transparent window and a second transparent window allowing at least the first and second items of medical information to be visible through the first transparent window and the second transparent window.



FIG. 1 illustrates various embodiments of a front surface 108 of a base label 100 for an object, such as a medication container, according to various embodiments. The base label 100 comprises a leading edge 102 and a trailing edge 104. While the leading edge 102 is oriented to the left and the trailing edge is oriented to the right as presented in FIG. 1, the orientation of the leading edge 102 and the trailing edge 104 could be reversed depending on which edge is first applied to the object. Both orientations are within the scope of the present disclosure. Base label front surface 108 may comprise writing or other base label indicia 106 thereon.


As used herein, the leading edge refers to the first edge to be affixed to the object and the trailing edge refers to the second edge to be affixed to the object or the overlapping leading edge. Depending on the orientation of the label and the object when the label is affixed to the object, either edge of the label may be the leading edge. The orientations presented in the figures are for convenience and are not intended to be limiting in any way.



FIG. 2 illustrates various embodiments of a back surface 206 of the base label 100. In various embodiments, the base label back surface 206 comprises two strips of adhesive 202 and 204 on or immediately adjacent to the leading and trailing edges, 102 and 104, respectively. Base label leading edge adhesive 202 may have a boundary 208 defined as its limit on the base label back surface 206. Base label trailing edge adhesive 204 may also have a boundary 210. While FIG. 2 illustrates that the adhesive strips 202 and 204 are generally close to the base label leading and trailing edges 102 and 104, respectively, it is understood that the adhesive strips 202 and 204 may be continuous or discontinuous, and may extend across any portion of the base label back surface 206, including the entire base label back surface 206. In various embodiments, a length of the base label 100 may be selected to be slightly longer than a circumference of the object on which it is placed, such that the trailing edge 104 overlaps the leading edge 102, and the trailing edge 104 is affixed to the leading edge 102. In various embodiments, the length of the base label 100 may be selected to be approximately the same as the circumference of the object on which it is placed, such that the leading edge 102 and the trailing edge 104 do not overlap.



FIG. 3 illustrates various embodiments of a top label front surface 306 of a top label 300. Top label 300 comprises a leading edge 302 and a trailing edge 304, and indicia 308 may be imprinted on the top label front surface 306.


Various embodiments of a back surface 402 of the top label 300 are illustrated in FIG. 4. The top label back surface 402 may comprise various indicia 408 printed thereon, as well as two strips of adhesive 404 and 406 on or immediately adjacent to the leading and trailing edges, 302 and 304, respectively. Top label leading edge adhesive 404 may have a boundary 410 defined as its limit on the top label back surface 402. Top label trailing edge adhesive 406 may also have a boundary 412. While FIG. 4 illustrates that the adhesive strips 404 and 406 are generally close to the top label leading and trailing edges 302 and 304, respectively, it is understood that the adhesive strips 404 and 406 may be continuous or discontinuous, and may extend across any portion of the top label back surface 402, including the entire top label back surface 402. In various embodiments, the adhesive strips 404 and 406 are confined to areas near the leading and trailing edges 302 and 304, respectively, so as not to obscure or interfere with the top label back surface indicia 408.


The base label adhesive 202, 204 and the top label adhesive 404, 406 may be applied in a variety of patterns as can be appreciated by one skilled in the art. The adhesive 202, 204, 404, 406 may be applied in in strips, dots, droplets, circles, rectangles, squares, triangles, lines, and the like, as well as combinations of patterns.


A length of the top label 300 may be selected to be slightly longer than a circumference of the object on which it is placed, such that the top label trailing edge 304 overlaps the top label leading edge 302, and the top label trailing edge 304 is affixed to the top label leading edge 302. In various embodiments, the length of the top label 300 may be selected to be approximately the same as the circumference of the object on which it is placed, such that both the leading edge 302 and the trailing edge 304 do not overlap and are affixed to the base label front surface 108.



FIG. 5A illustrates the application of the base label 100 to an exemplary container 500 according to various embodiments. The container 500 may be a glass or plastic bottle, or other type of container such as a metal can or a cardboard receptacle. The container may be round, rectangular, square, or any other shape known in the art. The term “container” is used here for convenience to describe exemplary embodiments. It is understood that the container may be any object, including non-containers. Container 500 may comprise a cap 502 removably secured to a body 504. Various embodiments of the body 504 may have an exterior surface 506 that comprises a upper label panel 508, a lower label panel 510, and a recessed surface 512 interposed between the upper label panel 508 and the lower label panel 510. As discussed below, the base label 100 may be applied to the container 500 at the recessed surface 512 between the upper label panel 508 and the lower label panel 510.


In various embodiments, the top label 300 may be rotatable about the base label 100, as discussed below. In these embodiments, the upper label panel 508 and lower label panel 510 may function to restrict upward and downward movement of the top label 300 in relation to the container 500 such that the top label 300 generally remains in a position covering at least a portion of the base label 100.



FIG. 5B illustrates the container 500 with the base label 100 affixed to the container 500. Initially, as illustrated in FIG. 5A, base label leading edge 102 is placed in contact with the recessed surface 512 of the container 500 and affixed to the container 500 by the leading edge adhesive strip 202. With relative motion between the container 500 and the base label 100, the base label 100 may be wrapped around the container 500 with the base label trailing edge 104 now overlapping the base label leading edge 102 such that the leading edge adhesive strip 202 holds the base label leading edge 102 to the container 500 while the trailing edge adhesive strip 204 holds the base label trailing edge 104 to the overlapped base label leading edge 102.


In various embodiments as illustrated in FIG. 6, the length of the base label 100 may be substantially the same as a circumference of the recessed surface 512 of the container 500, which may allow the base label leading edge 102 and base label trailing edge 104 to abut rather than overlap. However, it is also possible that the length of the base label 100 may be shorter than the circumference of the recessed surface 512, resulting in a gap 702 between the base label leading edge 102 and the base label trailing edge 104 when the base label 100 is affixed to the recessed surface as illustrated in FIG. 7. In both of these instances, the base label trailing edge adhesive strip 204 may adhere to the recessed surface 512 of the container 500, rather than the base label leading edge 102.


In various embodiments, the base label adhesive strips 202, 204 may comprise a permanent adhesive. In general, a permanent adhesive is one that does not readily release from a surface to which it adheres after the adhesive dries or cures. Using the base label 100 as an example, the permanent adhesive 202, 204 will tend not to release from the recessed surface 512, nor will it tend to release the base label leading edge 102 or trailing edge 104 once dried or cured. In order to remove the base label from the recessed surface 512, the base label 100 may have to be torn from the adhesive, or the adhesive layer 202, 204 may have to be fractured which may leave some of the adhesive on the recessed surface 512 and some of the adhesive on the base label leading edge 102 or trailing edge 104. Once the surfaces affixed with the permanent adhesive are separated, they may not be reattached.


In FIG. 8, the base label 100 is already affixed to the recessed surface 512 of the container 500, and the application of the top label 300 over the base label 100 is illustrated according to various embodiments. The top label leading edge 302 may be placed in contact with any portion of the base label front surface 108 and affixed to the base label front surface 108 by the top label leading edge adhesive strip 404. With relative motion between the container 500 and the top label 300, the top label 300 may be wrapped around the container 500 with the top label trailing edge 304 now overlapping the top label leading edge 302 such that the top label leading edge adhesive strip 404 holds the top label leading edge 302 to the base label 100 while the top label trailing edge adhesive strip 406 holds the top label trailing edge 304 to the overlapped top label leading edge 302.



FIG. 9 illustrates the operation of the base label 100 and the top label 300 according to various embodiments. Beginning with the container 500 with the base label 100 and the top label 300 in place as shown, for example, in FIG. 6, the top label trailing edge 304 may be detached from the top label leading edge 302 and at least partially peeled back as shown in FIG. 9. The combination of the base label 100 and the top label 300 in this configuration increases the amount of surface area available for viewing by a consumer or user of the container 500. Prior to detaching the top label trailing edge 304, the consumer may view the top label front surface 306. Upon detaching the top label trailing edge 304, the consumer may now view the top label back surface 402 and the base label front surface 108 in addition to the top label front surface 306.


One of at least three types of adhesive may be used for the top label leading edge adhesive 404. A first type of adhesive is the permanent adhesive as described above for the base label 100. When a permanent adhesive is used for the top label leading edge adhesive 404, the top label leading edge generally cannot be detached without inflicting damage to one or both of the top label 300 or the base label 100. This may be desirable for various embodiments where the top label 300 is not intended to be removed from the container 500.


A second type of adhesive that may be used for the top label leading edge adhesive 404 is a releasable adhesive. A releasable adhesive is one that will release from a surface to which it is attached once a sufficient mechanical force is applied. A releasable adhesive may be used, for example, when the top label back surface 402 comprises a coupon for a subsequent purchase of a product. The releasable adhesive may allow the consumer to easily remove the top label 300 for later use. In various embodiments, the releasable adhesive may be a breakaway adhesive. A breakaway adhesive may have limited ability to withstand shear stresses. Shear stresses may cause the adhesive bond created between the label (e.g., top label 300) and the surface to which it is affixed (e.g., the base label 100 or container 500) to fail along the adhesive. In general, a releasable or breakaway adhesive may not re-attach to a surface once removed.


A third type of adhesive that may be used for the top label leading edge adhesive 404 is a resealable adhesive. A resealable adhesive may release from a surface to which it is attached once a sufficient mechanical force is applied, similar to the releasable adhesive described above. However, the resealable adhesive may be re-attached to a surface by applying pressure. A resealable adhesive may be desirable when the top label back surface 402 or the base label front surface 108 comprise information that may be needed only on occasion. Thus, the consumer or user may detach the top label 300 when the information is needed, then re-attach the top label 300.


In various embodiments, the top label trailing edge adhesive 406 may be a releasable adhesive or a resealable adhesive, depending on the intended use of the top label 300. As described above, if the surfaces 108, 402 comprise information that is intended to stay with the container, the top label trailing edge adhesive 406 may be a resealable adhesive. In contrast, if the top label 300 is intended to be removed from the container 500, a releasable adhesive may be desirable.



FIG. 10 illustrates various embodiments of the top label 300 comprising a window 1002. The window 1002 may comprise a void in the top label 300 such that a portion of the base label 100 may be visible through the window. In various embodiments, the window 1002 may have a transparent covering (not shown). In various other embodiments, the window may comprise a transparent section of the top label 300 itself rather than a void. FIG. 10 illustrates the top label 300 partially wrapped about a container 1000, and base label 100 already in place on the container 1000. As shown, the top label leading edge adhesive 404 maintains the top label 300 coupled to the base label 100. The top label 300 may then be moved from the position illustrated in FIG. 10 to the position illustrated in FIG. 11 to secure the top label 300 about the container 1000. Top label trailing edge adhesive 406 may couple to the top label leading edge 302 if the top label leading edge 302 and trailing edge 304 overlap; otherwise, the top label trailing edge adhesive 406 may be coupled to the base label front surface 108.


Once the top label 300 is in position on the container 1000 as illustrated in FIG. 11, at least a portion of the base label indicia 106 may be visible through the window 1002. This may allow viewing of a first portion of the base label 100 without removing the top label 300. In various embodiments, the top label leading edge adhesive 404 may be a breakaway adhesive. Rotation of the top label 300 relative to the base label 100 may exert shear stresses on the breakaway adhesive, causing the adhesive bond affixing the top label leading edge 302 to the base label 100 to fail. The top label 300 may then be freely rotatable about the base label 100, and a second portion of the base label 100 may be visible when the top label 300 is rotated to a second position. The window 1002 may be rectangular as illustrated in FIGS. 10 and 11, or any other shape as needed for a particular application. For example, the window 1002 may be a slit that reveals an alphanumeric string on the base label 100. In various embodiments, the top label 300 may comprise more than one window 1002. Various embodiments in which the top label trailing edge adhesive 406 is a resealable or releasable adhesive may allow the top label 300 to be peeled back to reveal the top label back surface 402 and essentially the entire base label front surface 108 or to be removed from the container 1000, in addition to being rotatable.


One skilled in the art will readily recognize that labels may be applied to containers using a variety of methods and that there may be a variety of single-label and multi-label systems other than those described above. Any such application methods or label systems may be used with the present disclosure. The above descriptions are exemplary and not to be construed as limiting in any way. Examples of other application methods and label systems may be disclosed in U.S. Pat. Nos. 5,884,421, 6,086,697, 6,237,269, 6,402,872, 6,631,578, 6,649,007, 7,087,298, and 7,172,668.



FIGS. 12 and 13 illustrate a base label 100 and top label 300, respectively, that may comprise a rotating label medical information system for a container, such as a container 1405 (see FIG. 14) according to various embodiments. The base label indicia 106 may comprise a graphical illustration section 1205 and a text information section 1210. Although both the graphical illustration section 1205 and the text information section 1210 are shown in FIG. 12, various embodiments may include one of the graphical illustration section 1205 or the text information section 1210.


The graphical illustration section 1205 may comprise a plurality of individual first illustrations 1215-1240 (or images) representing at least a first item of medical information such as medical conditions, effects of taking medication, effects of not taking medication, potential drug interactions, or any other information the manufacturer of the medication in the container 1405 may desire to present to the consumer. In various embodiments, the first illustrations 1215-1240 may indicate progressively improving conditions related to taking the medication or progressively worsening conditions related to not taking the medication. In various embodiments, the first illustrations 1215-1240 may comprise a portion of a graphical representation that, when interacting with the top label 300 as described in detail below, forms a complete visual aid. The first illustrations 1215-1240 may be depicted in any color or combination of colors and may include any combination of alphanumeric characters.


In various embodiments, the text information section 1210 may comprise a plurality of individual messages 1245-1265 representing at least a second item of medical information, such as instructions, explanations, facts, or other information that coincide with and may be related to at least one of the first illustrations 1215-1240 in the graphical illustration section 1205. While FIG. 12 depicts the first illustrations 1215-1240 and the messages 1245-1265 vertically aligned with one another, other positioning is within the scope of the present disclosure.


The base label 100 may have a blank portion 1270 along the leading edge 102 that is essentially void of any base label indicia 106. As described previously, the trailing edge 104 may overlap the leading edge 102 when the base label 100 is applied to the container 1405. The blank portion 1270 provides a space for attachment of the trailing edge 104 without obscuring any of the base label indicia 106.


As illustrated in FIG. 13, various embodiments of the top label 300 may comprise indicia 308 relaying product-related information, safety-related information, manufacturer-related information, and the like. In various embodiments, the top label 300 may contain a window 1002 as described previously (see FIG. 10). The window 1002 may be divided into a transparent section 1305 and a semi-transparent section 1310. In the context of the present disclosure, “semi-transparent” is understood to mean that at least a portion of the section may be opaque or translucent, and at least a portion may be transparent. The semi-transparent section 1310 may comprise opaque markings thereon. The opaque markings may comprise a second illustration (or image) germane to the medication in the container 1405. For example, the medication may be for the treatment of heartburn, and the opaque markings in FIG. 13 may comprise an image of a stomach which is the source of the acidic material that causes heartburn. The opaque markings in various embodiments may define one or more non-opaque areas within the semi-transparent section 1310. A portion of the base label 100 may be visible through the non-opaque areas within the semi-transparent section 1310 and the transparent section 1305 when the top label 300 is positioned over the base label 100 as described more fully below. In various embodiments, the window 1002 may comprise the semi-transparent section 1310, and the transparent section 1305 may comprise a second transparent window. The transparent window 1002 and the second transparent window may be placed within separate portions of the top label 300. The separate portions may be adjacent as illustrated in FIG. 13, or may be spaced apart.



FIG. 14 illustrates the base label 100 positioned on the container 1405 according to various embodiments. As discussed above, the base label indicia 106 may comprise the graphical illustration section 1205 and the text information section 1210 printed on the front surface of the base label 100 such that the graphical illustration section 1205 and the text information section 1210 at least partially encircle the container 1405. FIGS. 15A through 15C illustrate the top label 300 in place over the base label 100 on the container 1405 according to various embodiments. The base label 100 and the top label 300 may comprise a medical condition rotating label system that may be used on the medication container 1405 to provide additional functionality to interactively illustrate information relating to the cause and symptoms of the medical condition to be treated by the medication, beneficial and adverse effects of the medication, or any other visual information. Providing such visual information may be advantageous to a consumer because the interactive and visual presentation of the information may lead to better understanding of the medical condition and its treatment. Better understanding by the consumer may result in more consistent consumption of the medication and more effective treatment of the medical condition. The visual information may be beneficial to the manufacturer of the product in the container 1405 by reducing the cost of the packaging and promoting increased consumption of the product.



FIG. 15A illustrates the top label 300 in place over the base label 100. As described previously, the top label 300 may be applied such that the top label 300 is rotatable around a circumference of the container 1405. In FIG. 15A, the top label 300 has been rotated in the direction of the arrow revealing at least one of the first illustrations 1215-1240 (in this example, first illustration 1215) through the semi-transparent section 1310 of the window 1002 in the top label 300. The first illustration 1215 may align with the second illustration in the semi-transparent section 1310. When such alignment is achieved, the first illustration 1215 may combine with the opaque markings (the second illustration) of the semi-transparent section 1310 to form an interactive visual aid according to various embodiments. In the example of FIG. 15A, the interactive visual aid is a depiction of a stomach with acid reflux extending into the esophagus.


In various embodiments, at least one of the messages 1245-1265 (in this example, message 1245) may be revealed simultaneously in the transparent section 1305 of the window 1002. The message 1245-1265 may compliment the visual aid created by the first illustration 1215-1240 and the opaque markings of the semi-transparent section 1310 of the window 1002. In the example of FIG. 15A, the consumer may rotate the top label 300 to reveal a visual aid representing the consumer's current medical condition (i.e., heartburn), and the message 1245 revealed in the transparent section 1305 of the window 1002 may provide, for example, dosing information or effects of consuming the dose. In this example, the message presented to the consumer is, “To Reduce Heartburn Symptoms Take 2 Tbsp”.



FIGS. 15B and 15C further illustrate the interactive nature of the medical condition rotating label system according to various embodiments. As the consumer further rotates the top label 300 in the direction of the arrow, a different one of the first illustrations 1215-1240 may be displayed through the semi-transparent section 1310 of the window 1002 and a different one of the messages 1245-1265 through the transparent section 1305 of the window 1002. In the example of FIG. 15B, the top label 300 has been rotated until the first illustration 1220 is displayed in the semi-transparent section 1310. The first illustration 1220 may combine with the opaque markings of the semi-transparent section 1310 to now depict a more serious case of heartburn. The corresponding message 1250 displayed through the transparent section 1305 may provide general information about the more serious condition such as, “A More Serious Sign of Acid Reflux Disease Is Consistent Heartburn”. In this example, the message 1250 provides general informational concerning the medical condition rather than specific information related to the use of the medication. FIG. 15C depicts the top label 300 further rotated such that first illustration 1225 is displayed in the semi-transparent section 1310 and message 1255 is displayed in the transparent section 1305. This example illustrates additional general information presented to the consumer. The message 1255 states, “Over Eating Can Cause Heartburn Symptoms,” and the combination of the first illustration 1225 and the opaque markings of the semi-transparent section 1310 depict a stomach full of food. The combination of the first illustration 1215-1240, the opaque markings, and the message 1245-1265 provides a visual aid that may help the consumer to better comprehend the medical condition and its treatment, as well as to more readily remember the information presented by the manufacturer of the medication or the health care provider.


As one skilled in the art will readily recognize, any type of visual representation comprising overlapping images or side-by-side images is within the scope of the present disclosure. FIGS. 12 and 13 illustrate a simple overlap of multiple images to form a desired static visual aid. More interactive visual aids may be created by using techniques to produce animated images. For example, FIGS. 16 and 17 illustrate various embodiments of a base label 100 and a top label 300, respectively, adapted to produce an animated visual aid with the use of barrier grid animation. Barrier grid animations may comprise a barrier image (or barrier grid) and an animated image.


As described previously for FIG. 12, the base label indicia 106 may comprise a graphical illustration section 1205 and a text information section 1210. Rather than a plurality of individual first illustrations such as first illustrations 1215-1240 of FIG. 12, the graphical illustration section 1205 according to the embodiments of FIG. 16 may comprise an animated image section 1610, such as a moiré pattern, and a non-animated image section 1605. The text information section 1210 may comprise individual messages 1615-1625 similar to that described previously for FIG. 12.


The semi-transparent section 1310 of the window 1002 of the top label 300 may comprise opaque markings that define a second illustration (for example, in FIG. 17 the opaque markings depict at least a portion of a human form, such as the head, neck, back, and shoulders). The opaque markings may further define one or more areas comprising a barrier grid.



FIG. 18 illustrates the base label 100 of FIG. 16 positioned on the container 1405 according to various embodiments. The graphical illustration section 1205 and the text information section 1210 may at least partially encircle the container 1405.



FIG. 19A illustrates the top label 300 in place over the base label 100. The top label 300 may be rotatable around a circumference of the container 1405. As the top label 300 is rotated to the position illustrated in FIG. 19A, the animated image section 1610 may be positioned under the barrier grid of the semi-transparent section 1310 of the window 1002 of the top label 300. The interaction of the barrier grid and the animated image section 1610 may produce an animated effect of waving lines, which may be understood by the consumer to represent intense shoulder pain. As the top label 300 is further rotated as depicted in FIG. 19B such that the non-animated section 1605 of the base label 100 is positioned under the barrier grid, then a non-motion image may be displayed that corresponds to relieved or lessened pain.



FIGS. 20 and 21 illustrate further various embodiments of overlapping images on the base label 100 and top label 300, respectively. In this example, the opaque markings of the semi-transparent section 1310 of the window 1002 of the top label 300 depict a sinus cavity. A portion of the sinus cavity image may be transparent to allow one or more of the individual first illustrations 2005-2025 to be visible when the base label 100 and the top label 300 overlap. The first illustrations may illustrate conditions within the sinus cavity.



FIG. 22 illustrates the base label 100 of FIG. 20 positioned on the container 1405 according to various embodiments. The graphical illustration section 1205 and the text information section 1210 may at least partially encircle the container 1405.



FIG. 23A illustrates the top label 300 in place over the base label 100. The top label 300 may be rotatable around a circumference of the container 1405. As the top label 300 is rotated to the position illustrated in FIG. 23A, at least one of the first illustrations 2005-2025 (in this example, first illustration 2005) may be visible through the semi-transparent section 1310 of the window 1002 of the top label 300. The first illustration 2005 may align with the second illustration in the semi-transparent section 1310. When such alignment is achieved, the first illustration 2005 may combine with the opaque markings (the second illustration) of the semi-transparent section 1310 to form an interactive visual aid according to various embodiments. In the example of FIG. 23A, the interactive visual aid is a depiction of a swollen sinus cavity. Additionally, the message 2030 corresponding to the first illustration 2005 may be visible through the transparent section 1305 of the window 1002 to augment the visual aid created by the overlap of the of the top label 300 and the base label 100.


Further rotation of the top label 300 in the direction indicated by the arrow in FIG. 23B may cause a different one of the first illustrations 2005-2025 to be displayed through the semi-transparent section 1310 of the window 1002 and a different one of the messages 2030-2050 to be displayed through the transparent section 1305 of the window 1002.


In various embodiments, the first illustrations 2005-2025 may be printed in a variety of colors to further enhance the effect of the visual aid. For example, various shades of red could be used for each of the first illustrations 2005-2025 to depict different intensities of sinus inflammation. In addition, the intensity of the shading may vary from one first illustration 2005-2025 to the other to depict the intensity of the sinus inflammation. For example, the first illustration 2005 may be depicted in a dark and intense shade of red to indicate a severe case of sinus infection, while the first illustration 2025 may be depicted in a light shade of red that is only marginally visible to indicate the relieving effects of the medication.



FIGS. 24 and 25 further illustrate the use of barrier grid animation to produce an animated visual aid. The graphical illustration section 1205 of the base label indicia 106 may comprise a plurality of individual first illustrations 2405-2425. Each first illustration 2405-2425 may comprise two or more animated images, where the animated images are separated into thin strips and merged together such that each image is slightly offset from the next. For example, first illustration 2405 comprises an image of a person in a standing position and an image of a person is a squatting position. The base label 100 may also comprise a text information section 1210 comprising a plurality of individual messages 2430-2450 as described previously.


In various embodiments as illustrated in FIG. 25, the window 1002 may comprise a semi-transparent section 1310 comprising a series of spaced apart lines (i.e., the barrier image). A distance between the spaced apart lines may be approximately equal to a distance between the strips of the animated images of the first illustrations 2405-2410.



FIG. 26 illustrates the base label 100 positioned on the container 1405 according to various embodiments. In FIG. 27A, the top label 300 is in place over the base label 100, and the top label 300 has been rotated such that the semi-transparent section 1310 is positioned over the first illustration 2415. The message 2440 corresponding to the first illustration 2415 may be visible in the transparent section 1305 of the window 1002. As illustrated in FIG. 27A, the barrier image of the semi-transparent section 1310 may be positioned such that the spaced apart lines are blocking the image of the person in a standing position, allowing the image of the person in a bent over position to be visible in the space between the spaced apart lines. In FIG. 27B, the top label has been rotated only slightly so that the spaced apart lines are now blocking the image of the person in a bent over position and allowing the image of the person in a standing position to be visible. Because the top image was rotated only slightly, message 2440 may be visible both in FIG. 27A and in FIG. 27B.


The top label 300 may comprise a dual ply (or multi-ply) construction in which a ply in contact with the base label 100 is a material selected for low sliding friction characteristics. The low sliding friction characteristics may enhance the ease of rotating and sliding the top label 300 about the base label 100. In various embodiments, the top label 300 ply in contact with the base label 100 may be coated with a substance to impart the low sliding friction characteristics.



FIG. 28 illustrates a general flow chart of various embodiments of a method 2800 for communicating medical information associated with a container. A base label 100 may be applied to a container 1405 (step 2805). The base label 100 may have a back surface 206 and a front surface 108. At least a first and second item of medical information may be printed or placed on the front surface 108 of the base label 100 (step 2810). At step 2815, at least a portion of the base label 100 may be covered with a rotating top label 300. In various embodiments, the base label 100 may be coupled to the container 1405 while the top label 300 is free to rotate about the base label 100. A window 1002 may be placed within a portion of the rotating top label 300 at step 2820. The window 1002 may comprise a first and a second transparent window placed within separate portions of the opaque rotating top label. The first and second transparent windows may be placed such that at least the first and second items of medical information are visible through the first and second transparent windows. As the top label 300 is rotated about the base label 100, one or more other items of medical information may alternately be visible through the first and second transparent windows. In various embodiments, more than one of the items of medical information may be visible through each of the first and second transparent windows.


In various embodiments, all or a portion of the base label indicia 106 may be imprinted, embossed, or molded directly on an outer surface of the container 1405 in place of all or a portion of the base label 100. The imprinting or embossing may be carried out using any printing or image transfer method known in the art. In various embodiments, the printing or image transfer method may be an offset process in which an image is transferred from a plate to an intermediate carrier, then to the outer surface of the container 1405. The offset process may also involve lithographic techniques. Other printing or image transfer methods may comprise, for example, flexography, pad printing, relief printing, rotogravure, screen printing, and electrophotography. According to various embodiments, the base label indicia 106 may be digitally printed on the outer surface of the container 1405 using, for example, inkjet printing or laser printing. Chemical printing technologies, such as blueprint or diazo print may also be used in various embodiments.


Spatially relative terms such as “under”, “below”, “lower”, “over”, “upper”, and the like, are used for ease of description to explain the positioning of one element relative to a second element. These terms are intended to encompass different orientations of the device in addition to different orientations than those depicted in the figures. Further, terms such as “first”, “second”, and the like, are also used to describe various elements, regions, sections, etc. and are also not intended to be limiting. Like terms refer to like elements throughout the description.


As used herein, the terms “having”, “containing”, “including”, “comprising”, and the like are open ended terms that indicate the presence of stated elements or features, but do not preclude additional elements or features. The articles “a”, “an” and “the” are intended to include the plural as well as the singular, unless the context clearly indicates otherwise.


The present invention may be carried out in other specific ways than those herein set forth without departing from the scope and essential characteristics of the invention. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive, and all changes coming within the meaning and equivalency range of the appended claims are intended to be embraced therein.

Claims
  • 1. A rotating label medical information system for a container, the system comprising: a base label adhered to the container, the base label having a back surface and a front surface;at least a first item of medical information on the front surface of the base label, the first item comprising a first partial image;at least a second item of medical information of the front surface of the base label, wherein the second item is textually displayed;an opaque rotating top label covering at least a portion of the front surface of the base label; anda first transparent window and a second transparent window placed within separate portions of the opaque rotating top label, the first transparent window comprising a second partial image thereon, the first and second partial images aligning to form a complete image in the first transparent window and the second item of medical information visible in the second transparent window when the opaque top label is rotated about the base label.
  • 2. The system of claim 1, wherein the second item of medical information is related to the complete image.
  • 3. The system of claim 2, wherein the complete image depicts a medical condition and the second item of medical information textually describes the medical condition.
  • 4. The system of claim 1, wherein the complete image depicts a portion of a human body.
  • 5. The system of claim 4, wherein the complete image depicts a sinus cavity.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to provisional U.S. Patent Application Ser. No. 61/524,254, filed on Aug. 16, 2011, titled “Method and Device for Illustrating a Medical Condition and the Results from Taking the Medication Within the Packaging,” which is hereby incorporated by reference in its entirety.

US Referenced Citations (318)
Number Name Date Kind
332208 Noel Dec 1885 A
736035 Stevenson Aug 1903 A
1054826 Cole Mar 1913 A
1064576 Washburn Jun 1913 A
1145367 Herter Jul 1915 A
1312611 Chess Aug 1919 A
1317660 Carlson Sep 1919 A
1334031 Hahn Mar 1920 A
1387625 Stein Aug 1921 A
1486313 Van Antwerp Mar 1924 A
2013615 Haviland Fontan Le Roy Sep 1935 A
2013616 Rettenmeyer Sep 1935 A
2069609 Hanson Feb 1937 A
2129364 Simons et al. Sep 1938 A
2441607 Walls May 1948 A
2468000 Taylor Apr 1949 A
2487274 Schaffer Nov 1949 A
2504076 Lindblom Apr 1950 A
2706464 North Apr 1955 A
2738564 Guianne Mar 1956 A
2739564 North Mar 1956 A
2844893 Keller Jul 1958 A
2860431 Barnum Nov 1958 A
2931657 Lewis Apr 1960 A
2935814 Freeze May 1960 A
2971283 Parker Feb 1961 A
3233770 Waters Feb 1966 A
3278182 Lescher Oct 1966 A
3374911 White Mar 1968 A
D210767 Anglada Apr 1968 S
3375954 Arvid Honkanen et al. Apr 1968 A
3468467 Amberg Sep 1969 A
3488880 Taylor Jan 1970 A
3523623 Dorn Aug 1970 A
3542229 Beyerlein et al. Nov 1970 A
3604584 Shank Sep 1971 A
3633781 Zapata Jan 1972 A
3733002 Fujio May 1973 A
3750317 Morgan Aug 1973 A
3766882 Babbitt, III Oct 1973 A
3779829 Wolff Dec 1973 A
3865671 Kronsder Feb 1975 A
3874977 Pyles Apr 1975 A
3960713 Carey Jun 1976 A
4044889 Orentreich et al. Aug 1977 A
4057251 Jones et al. Nov 1977 A
4072553 Braker et al. Feb 1978 A
4203240 Goodwin May 1980 A
4312523 Haines Jan 1982 A
4318683 Fishbaugh et al. Mar 1982 A
4381615 Lonsmin May 1983 A
4405045 Villa-Real Sep 1983 A
4473429 Crankshaw Sep 1984 A
4505497 Katzman Mar 1985 A
4518450 Warmann May 1985 A
4533586 Roule et al. Aug 1985 A
4567681 Fumei Feb 1986 A
4589943 Kimball et al. May 1986 A
4658974 Fujita et al. Apr 1987 A
4680080 Instance Jul 1987 A
4700976 Loose Oct 1987 A
4724973 Shah Feb 1988 A
4727667 Ingle Mar 1988 A
4732411 Siegel Mar 1988 A
4844760 Dickey Jul 1989 A
4877119 Hosking Oct 1989 A
4918604 Baum Apr 1990 A
4920912 Kirkling May 1990 A
4955153 Albrecht et al. Sep 1990 A
D311423 DeSantis Oct 1990 S
5017261 Zodrow et al. May 1991 A
5048870 Mangini et al. Sep 1991 A
5062917 Zodrow Nov 1991 A
5076613 Kovacs Dec 1991 A
5078826 Rogall Jan 1992 A
5116452 Eder May 1992 A
5154448 Griffin et al. Oct 1992 A
5207011 Coulthard May 1993 A
5209367 Van Musscher et al. May 1993 A
5215622 Schmelzer Jun 1993 A
5263743 Jones Nov 1993 A
5264265 Kaufmann Nov 1993 A
5269085 Chiapetta et al. Dec 1993 A
5284363 Gartner et al. Feb 1994 A
5321933 Seifert et al. Jun 1994 A
5324559 Brombacher Jun 1994 A
5339998 Warren Aug 1994 A
5342093 Weernink Aug 1994 A
5363576 Piana et al. Nov 1994 A
5370754 Soloman Dec 1994 A
5403635 Hoffman Apr 1995 A
5403636 Crum Apr 1995 A
5405482 Morrissette et al. Apr 1995 A
5462488 McKillip Oct 1995 A
5484167 Donaldson et al. Jan 1996 A
D368234 Dickinson et al. Mar 1996 S
5525383 Witkowski Jun 1996 A
5605230 Marino, Jr. et al. Feb 1997 A
5605730 Treleaven Feb 1997 A
5639529 Gozdecki et al. Jun 1997 A
D383038 Willbrandt Sep 1997 S
D386947 Lapierre et al. Dec 1997 S
5712021 Hernandez Jan 1998 A
5727766 Mayo Mar 1998 A
5727819 Grosskopf et al. Mar 1998 A
5738382 Grosskopf et al. Apr 1998 A
5741381 Dolence et al. Apr 1998 A
5758096 Barsky et al. May 1998 A
5799525 Johnson et al. Sep 1998 A
5800893 Harden Sep 1998 A
5809674 Key Sep 1998 A
5829789 Treleaven et al. Nov 1998 A
5830550 Treleaven et al. Nov 1998 A
5842633 Nurse Dec 1998 A
5863628 Barry Jan 1999 A
5883370 Walker et al. Mar 1999 A
5884421 Key Mar 1999 A
5953170 Glancy Sep 1999 A
5975582 Treleaven Nov 1999 A
6027780 Treleaven et al. Feb 2000 A
6035568 Grosskopf et al. Mar 2000 A
6047488 Tuszkiewicz Apr 2000 A
6048423 Barrash et al. Apr 2000 A
6057019 Barry May 2000 A
D428307 Yeandel Jul 2000 S
6086697 Key Jul 2000 A
6120637 Barry Sep 2000 A
6129802 Key Oct 2000 A
6129959 Mercer et al. Oct 2000 A
6158612 Alpert Dec 2000 A
D436499 Pritchard et al. Jan 2001 S
6212803 Key Apr 2001 B1
6213520 Treleaven et al. Apr 2001 B1
6237269 Key May 2001 B1
6253438 Jespersen Jul 2001 B1
6254138 Rawlings et al. Jul 2001 B1
6258200 Kassab Jul 2001 B1
6267672 Vance Jul 2001 B1
D446687 Furman et al. Aug 2001 S
6270121 Dolan et al. Aug 2001 B1
6274236 Shacklett et al. Aug 2001 B1
6276533 Kaplan Aug 2001 B1
6328832 Otruba et al. Dec 2001 B1
6329034 Pendry et al. Dec 2001 B1
6360462 Mengel Mar 2002 B1
6385878 Key May 2002 B1
6398263 Treleaven et al. Jun 2002 B2
6402872 Key Jun 2002 B1
6413345 Treleaven Jul 2002 B1
D461369 Sims et al. Aug 2002 S
6428639 Oldenburg et al. Aug 2002 B1
6431241 Gonzalo Aug 2002 B1
6454094 Salani Sep 2002 B1
6550171 De Werra et al. Apr 2003 B1
6550512 Yang Apr 2003 B2
6561246 Yang May 2003 B2
6575216 Yang Jun 2003 B2
6581773 Kaplan Jun 2003 B2
6616189 Raming Sep 2003 B2
6622878 Frey Sep 2003 B1
6631578 Key Oct 2003 B2
6649007 Key Nov 2003 B1
6669804 Pendry et al. Dec 2003 B2
6722568 Blanford et al. Apr 2004 B2
6737137 Franko, Sr. et al. May 2004 B2
6752431 Matthews et al. Jun 2004 B1
6755442 Franko, Sr. et al. Jun 2004 B2
6779480 Zamjahn Aug 2004 B2
6786515 Franko, Sr. Sep 2004 B2
6793075 Jeter Sep 2004 B1
6793755 Schaupp et al. Sep 2004 B2
6811640 Franko, Sr. Nov 2004 B2
6904867 Zamjahn Jun 2005 B2
7010877 Geary Mar 2006 B2
D526847 Freeman Aug 2006 S
7087298 Key Aug 2006 B2
D527583 Freeman Sep 2006 S
D533748 Bresler Dec 2006 S
7172220 Franko, Sr. Feb 2007 B2
7172668 Key Feb 2007 B2
7179514 Olsen et al. Feb 2007 B2
D545429 Hays Jun 2007 S
7325510 Giewercer Feb 2008 B2
7601410 Matthews et al. Oct 2009 B2
7621231 McNeely Nov 2009 B2
7628427 Adler et al. Dec 2009 B2
7782479 Handa et al. Aug 2010 B2
7875142 Matthews et al. Jan 2011 B2
7886909 Robinson Feb 2011 B2
7926851 Kaufman Apr 2011 B2
8037628 Kaufman Oct 2011 B2
8043993 Roth et al. Oct 2011 B2
D649396 Wilkens et al. Nov 2011 S
8142596 Valenti, Jr. et al. Mar 2012 B1
8245752 Lingier et al. Aug 2012 B2
8272562 Ziegler Sep 2012 B2
8413884 Lim et al. Apr 2013 B2
8424761 Yanagi Apr 2013 B2
D682088 de Urquijo Carmona May 2013 S
8479919 Kaplan et al. Jul 2013 B2
8709198 Key Apr 2014 B2
8727220 Key May 2014 B2
D706624 Key Jun 2014 S
D706625 Key Jun 2014 S
8814217 Key Aug 2014 B2
20010004152 Treleaven et al. Jun 2001 A1
20010017181 Otruba et al. Aug 2001 A1
20010025442 Key Oct 2001 A1
20010045741 Shacklett et al. Nov 2001 A1
20010050242 Kaplan Dec 2001 A1
20020015813 Pendry et al. Feb 2002 A1
20020017784 Merry et al. Feb 2002 A1
20020029635 Kremen Mar 2002 A1
20020038685 Key Apr 2002 A1
20020096261 Yang Jul 2002 A1
20020096262 Yang Jul 2002 A1
20020096264 Yang Jul 2002 A1
20020104613 Key Aug 2002 A1
20020130182 Mondie Sep 2002 A1
20020139292 Giewercer Oct 2002 A1
20020185212 Schaupp et al. Dec 2002 A1
20020193225 Raming Dec 2002 A1
20030006606 Franko, Sr. et al. Jan 2003 A1
20030012911 Campbell Jan 2003 A1
20030015105 Dewig et al. Jan 2003 A1
20030030270 Franko, Sr. et al. Feb 2003 A1
20030091819 Franko, Sr. May 2003 A1
20030118768 Sellars Jun 2003 A1
20030137145 Fell et al. Jul 2003 A1
20030175463 Olsen et al. Sep 2003 A1
20030189490 Hogerton et al. Oct 2003 A1
20030201064 Treleaven et al. Oct 2003 A1
20040108237 McClintock Jun 2004 A1
20040123565 Rice et al. Jul 2004 A1
20040166277 Key Aug 2004 A1
20040188998 Henthorn Sep 2004 A1
20040197513 Shacklett et al. Oct 2004 A1
20040207193 Franko, Sr. Oct 2004 A1
20040247863 Scott Dec 2004 A1
20050038558 Keene Feb 2005 A1
20050056203 Giewercer Mar 2005 A1
20050097004 Masse Blume May 2005 A1
20050120600 Harman Jun 2005 A1
20050181165 Franko Aug 2005 A1
20050183982 Giewercer Aug 2005 A1
20050190914 Chen et al. Sep 2005 A1
20050209870 Alden Sep 2005 A1
20060029761 Matthews et al. Feb 2006 A1
20060032923 Krupa Feb 2006 A1
20060078701 Glasier Apr 2006 A1
20060145471 Franko Jul 2006 A1
20060249950 Kenney et al. Nov 2006 A1
20070029787 Loftin et al. Feb 2007 A1
20070034103 Kaufman Feb 2007 A1
20070043530 O'Rourke Feb 2007 A1
20070119542 Williams et al. May 2007 A1
20070209753 Gonzalez et al. Sep 2007 A1
20070209755 Smith Sep 2007 A1
20070213214 Roth et al. Sep 2007 A1
20070221319 Morgan Sep 2007 A1
20070222205 Handa et al. Sep 2007 A1
20070252379 Bethune et al. Nov 2007 A1
20070299693 Jung et al. Dec 2007 A1
20080003391 Franko et al. Jan 2008 A1
20080003410 Shacklett et al. Jan 2008 A1
20080010874 Londino Jan 2008 A1
20080014344 Fort et al. Jan 2008 A1
20080073902 Franko Mar 2008 A1
20080121688 Harrop May 2008 A1
20080176955 Heck et al. Jul 2008 A1
20080208694 Baggott Aug 2008 A1
20080233405 Dronzek Jr. Sep 2008 A1
20080303264 Kaufman Dec 2008 A1
20080303265 Kaufman Dec 2008 A1
20090236023 Lingier et al. Sep 2009 A1
20090255623 Bagung et al. Oct 2009 A1
20090264815 Grogan, Jr. Oct 2009 A1
20090265188 Lamy et al. Oct 2009 A1
20090294521 de la Huerga Dec 2009 A1
20100043267 Sterling Feb 2010 A1
20100044438 Chen et al. Feb 2010 A1
20100084077 Matthews et al. Apr 2010 A1
20100101681 Kramer et al. Apr 2010 A1
20100228615 Hays Sep 2010 A1
20100240133 Brivanlou et al. Sep 2010 A1
20100295916 Kaufman Nov 2010 A1
20100300599 Fort et al. Dec 2010 A1
20100307947 Marden et al. Dec 2010 A1
20110061802 Raming Mar 2011 A1
20110151115 Lingier Jun 2011 A1
20110169602 Gaffney Jul 2011 A1
20110185606 Londino Aug 2011 A1
20110233095 Seidl Sep 2011 A1
20120006712 Kaplan et al. Jan 2012 A1
20120010299 Kaplan et al. Jan 2012 A1
20120037299 Baeta et al. Feb 2012 A1
20120085828 Ziegler Apr 2012 A1
20120118503 Lorence et al. May 2012 A1
20120125526 Key May 2012 A1
20120175336 Miller et al. Jul 2012 A1
20120268837 Rittenburg et al. Oct 2012 A1
20120279632 Lingier et al. Nov 2012 A1
20120292219 Terwilliger et al. Nov 2012 A1
20130025175 Key Jan 2013 A1
20130025529 Key Jan 2013 A1
20130026056 Key Jan 2013 A1
20130026747 Key Jan 2013 A1
20130033031 Key Feb 2013 A1
20130036634 Key Feb 2013 A1
20130036641 Key Feb 2013 A1
20130037619 Key Feb 2013 A1
20130043157 Key Feb 2013 A1
20130062239 Key Mar 2013 A1
20130129971 Key et al. May 2013 A1
20140076766 Key Mar 2014 A1
20140210198 Key Jul 2014 A1
20140224889 Key Aug 2014 A1
20140339120 Key Nov 2014 A1
Foreign Referenced Citations (57)
Number Date Country
932891 Apr 2002 AT
1165378 Sep 2004 AT
723118 Nov 2000 AU
932891 Apr 2002 BE
1165378 Sep 2004 BE
932891 Apr 2002 CH
1165378 Sep 2004 CH
103890826 Jun 2014 CN
69711903.3-08 Apr 2002 DE
1165378 Sep 2004 DE
85214 Mar 1958 DK
932891 Apr 2002 DK
285514 Oct 1988 EP
932891 Apr 2002 EP
1165378 Sep 2004 EP
2742501 Jun 2014 EP
932891 Apr 2002 ES
965522 Sep 1950 FR
1114750 Apr 1956 FR
1347102 Nov 1963 FR
2460260 Jan 1981 FR
285514 Oct 1988 FR
2613519 Oct 1988 FR
2677786 Dec 1992 FR
932891 Apr 2002 FR
1165378 Sep 2004 FR
932891 Apr 2002 GB
1039770 May 2002 HK
1021056 Jul 2002 HK
932891 Apr 2002 IE
1165378 Sep 2004 IE
327286 Jul 1935 IT
932891 Apr 2002 IT
204456 Sep 2002 MX
225535 Jan 2005 MX
227727 May 2005 MX
932891 Apr 2002 NL
334683 Nov 1999 NZ
1565 Jul 1888 SE
932891 Apr 2002 SE
WO9819289 May 1998 WO
WO0048161 Aug 2000 WO
WO03017174 Feb 2003 WO
WO2007020628 Feb 2007 WO
WO2012071355 May 2012 WO
WO2013015838 Jan 2013 WO
WO2013015839 Jan 2013 WO
WO2013016364 Jan 2013 WO
WO2013016461 Jan 2013 WO
WO2013019907 Feb 2013 WO
WO2013022495 Feb 2013 WO
WO2013022508 Feb 2013 WO
WO2013023221 Feb 2013 WO
WO2013025947 Feb 2013 WO
WO2013039578 Mar 2013 WO
WO2013043618 Mar 2013 WO
WO2014047077 Mar 2014 WO
Non-Patent Literature Citations (19)
Entry
International Search Report and Written Opinion mailed May 25, 2012 in Patent Cooperation Treaty Application No. PCT/US12/22609, filed Jan. 25, 2012.
International Search Report and Written Opinion mailed May 23, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/022610, filed Jan. 25, 2012.
International Search Report and Written Opinion mailed Oct. 9, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/048021, filed Jul. 24, 2012.
International Search Report and Written Opinion mailed Oct. 23, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/050643, filed Aug. 13, 2012.
International Search Report and Written Opinion mailed Nov. 30, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/055948, filed Sep. 18, 2012.
International Search Report and Written Opinion mailed Jul. 26, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/037395, filed May 10, 2012.
International Search Report and Written Opinion mailed Oct. 16, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/048201, filed Jul. 25, 2012.
International Search Report and Written Opinion mailed Jul. 9, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/031670, filed Mar. 30, 2012.
International Search Report and Written Opinion mailed Oct. 23, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/051228, filed Aug. 16, 2012.
International Search Report and Written Opinion mailed Oct. 16, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/049234, filed Aug. 1, 2012.
International Search Report and Written Opinion mailed Aug. 27, 2012 in Patent Cooperation Treaty Application No. PCT/US2012/040301, filed May 31, 2012.
Newswire, “AccuDial(R) Pharmaceutical, Inc. can put an end to underdosing and overdosing with new line of children's over-the-counter medications”, Jul. 8, 2010 [retrieved Dec. 12, 2013]. Retrieved from Internet: <http://www.newswire.ca/en/story/646945/accudial-r-pharmaceutical-inc-can-put-an-end-to-underdosing-and-overdosing-with-new-line-of-children-s-over-the-counter-medications>.
Accudial Pharmaceutical, Inc. company website, www.accuratedose.com, Oct. 30, 2010 [retrieved Aug. 7, 2012). Retrieved from Internet: <http://web.archive.org/web/20101030115353/http://www.accuratedose.com.ca—english/home>.
Anonymous, “Chest congestion (guaifenesin) liquid”, Internet article, http://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?id=25295., (Oct. 26, 2009).
Anonymous, “Pharmaceutical & medical packaging news”, The packaging magazine for the healthcare industry, 16:12:76-78, Internet article, http://www.accuratedose.com/corporate/assets/pdf/PMP—MagReprinIDec08.pdf, (Dec. 12, 2008).
A. Abramson, “Start-up has twist on safe doses for kids”, Internet article, http://www.accuratedose.com/corporate/assets/pdf/50840—ACC—PBP—Article. pdf, (Jul. 27, 2009).
Anonymous, “Chest congestion guaifenesin oral solution expectorant”, Internet article, http://accuratedose.com/us—english/producUnformation/chest—congestion.html, (Aug. 24, 2011).
International Search Report and Written Opinion mailed Apr. 2, 2012 in Patent Cooperation Treaty Application No. PCT/US2011/061739, filed Nov. 21, 2011.
International Search Report and Written Opinion mailed Feb. 28, 2014 in Patent Cooperation Treaty Application No. PCT/US2013/060220, filed Sep. 17, 2013.
Related Publications (1)
Number Date Country
20130043157 A1 Feb 2013 US
Provisional Applications (1)
Number Date Country
61524254 Aug 2011 US